As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of US ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the broader market.